The CDC is considering a major shift in its COVID-19 vaccine recommendations, moving from yearly boosters for all adults and children over six months to a risk-based approach focusing on vulnerable populations. This potential change, discussed by a CDC panel, could significantly impact pharmaceutical companies' profits. The decision follows a historically delayed meeting amid concerns about potential influence from the new health chief, Robert F. Kennedy Jr., a vaccine skeptic. A final vote is expected in June. Currently, low public enthusiasm and the US's outlier approach to widespread booster recommendations contribute to the debate.

Prepared by Olivia Bennett and reviewed by editorial team.